(305 days)
Not Found
No
The device description mentions "machine vision detection" but does not explicitly state the use of AI or ML algorithms for this detection or any other function. The performance studies and key metrics are standard for a diagnostic device and do not indicate AI/ML involvement.
No
Explanation: This device is an in vitro diagnostic (IVD) device used to monitor Oral Anticoagulation Therapy (OAT) warfarin by determining INR. It is not designed to provide or administer therapy.
Yes
Explanation: The "Intended Use / Indications for Use" section explicitly states, "The microNR System is intended for in vitro diagnostic use at the point-of-care." Additionally, it is used for the "determination of International Normalized Ratio (INR) to monitor Oral Anticoagulation Therapy (OAT) warfarin," which is a diagnostic purpose.
No
The device description explicitly states the system is comprised of a portable measuring device (microINR® Meter) and test strips (microINR® Chips), which are hardware components.
Yes, this device is an IVD (In Vitro Diagnostic).
The Intended Use section explicitly states: "The microNR System is intended for in vitro diagnostic use at the point-of-care."
Furthermore, the device performs a test (determination of International Normalized Ratio (INR)) on a biological sample (fresh capillary whole blood) to provide information about a patient's health status (monitoring Oral Anticoagulation Therapy (OAT) warfarin). This aligns with the definition of an in vitro diagnostic device.
N/A
Intended Use / Indications for Use
microINR System:
The microlNR System (consisting of the microINR Chip) is intended for multiple-patient use by professional healthcare providers for the determination of International Normalized Ratio (INR) to monitor Oral Anticoagulation Therapy (OAT) warfarin. The microINR System uses fresh capillary whole blood. The microNR System is intended for in vitro diagnostic use at the point-of-care.
The microlNR System is intended for use in patients 18 years of age and older. Patients must be stabilized (≥ 6 weeks) on warfarin.
Caution: The microINR System is not intended for use in patients who are transitioning from heparin treatment to warfarin therapy. The microINR System is not intended to be used for screening purposes.
The microINR chips are only intended to be used with the microINR meter.
microINR Control Level A / microINR Control Level B:
The microlNR Control is intended for quality control performed on the microINR Meter when used with the disposable microINR Chips.
iLine Microsystems has available two microNR Control Levels (A and B) to perform quality control checks in the therapeutic range on the microINR System.
The microINR Control is intended for professional use only.
Product codes (comma separated list FDA assigned to the subject device)
GJS, GGN
Device Description
The microINR® System is comprised of a portable measuring device (microINR® Meter) and test strips (microINR® Chips) in which the capillary blood sample flows through capillary action.
The microINR® Chip contains a reagent in dried form which consists of thromboplastin, and contains two symmetrical regions, the measuring channel and a control channel. The microINR® Meter measures International Normalized Ratio (INR) based on a Prothrombin Time (PT) assay carried out in the microINR® Chip based on microfluidic technology with machine vision detection.
The microINR® System has a multi-level On-board Quality Control. Multiple key functions and elements of the system are checked and if deviations are detected, error messages are displayed and test results are not reported.
In addition to the microINR® On-Board Controls, the microINR® Control has been developed as an optional liquid quality control solution. The microINR® Control must be used only by healthcare professionals in order to meet the regulatory compliance requirements applicable to the facility where they are to be used.
The microINR® Control contains lyophilized human citrated plasma from healthy donors (not heparinized plasma or plasma samples under oral anticoagulant therapy) modified by means of a dedicated process to simulate an abnormal coagulation sample and a calcium chloride solution. Before use, the lyophilized plasma must be reconstituted with the calcium chloride solution.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
18 years of age and older.
Intended User / Care Setting
professional healthcare providers / point-of-care.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
9.1. Analytical Performance
a) Precision/Repeatability:
Repeatability:
The repeatability study was performed at three clinical sites, testing capillary samples from normal subjects and patients on warfarin therapy. Multiple Chip lots, Meters and Operators were included in the study. Two capillary samples (two fingersticks) were collected from each subject resulting into a total of 269 paired tests.
b) Reproducibility/Intermediate Precision:
Device reproducibility:
The study was performed using two levels of plasma samples. INR was determined in both plasma samples by each device each day.
c) Linearity/assay reportable range:
A linearity study is not applicable for the microINR® System.
The assay reportable range (0.8 - 6.0 INR) of the microINR® System was established through method comparison studies against the reference device (Instrumentation Laboratory ACL TOP® 500 laboratory analyzer). HemosIL® RecombiPlasTin 2G Reagent was used for prothrombin time (PT) determinations. Data collected across the assay reportable range from the method comparison studies were used to demonstrate linearity on the microINR® System.
d) Traceability, stability, expected values (controls, calibrators, or methods):
Traceability: Each lot of microINR® Chips is factory calibrated to a reference lot of human recombinant thromboplastin traceable to the World Health Organization International Reference Preparation.
microINR® Chips Stability:
Real Stability: The stability of 15 months shelf life was established by storing three microINR® Chip lots at 25 ℃ (77 ℃) (60% Relative Humidity (RH)) and testing using fresh whole blood samples.
In-Use Stability: In-use stability was tested to prove that the microINR® Chips can be kept outside the pouch before measurement for at least 6 hours when directly exposed to 35 ℃ (95 ℃ (95 ℃ relative humidity RH. It was assessed by exposing the Chips out of their pouches to 35℃ (95 ℃), 80% RH storage and testing using fresh whole blood samples.
Transport Stability: microINR® Chips and its package were validated by a transport stability study. Package evaluation was assessed and the performance of the microINR® Chips was tested using fresh whole blood samples.
Optional Liquid Controls Stability:
Stability: The stability of the microINR® Controls is 12 months stored at refrigerated conditions of 2-8 ℃ according to the data projected from an accelerated study performed with one lot of each microINR® Control level stored at 24.0 ℃ ± 1.1 ℃ (75.2 °F ± 34.0 °F) for up to 106 days. The in-use stability of the microINR® Controls is 10 minutes (upon reconstitution) at room temperature (15-25 °C, 59-77 °F).
Target Assignment: The target assignment is performed by using at least 10 vials of each microINR® Control lot performing two runs per day during several days. A total of 30 duplicated tests are used to determine the mean INR determination (target value).
e) Detection Limit:
The sensitivity to factors II, V, VII and X of the microINR® System was performed by mixing varying amounts of factor II, V, VII and X deficient plasma, pool normal plasma and red blood cells to final factor concentrations between 100% and 0%. These samples were then tested using nine microINR® Meters and three microINR® Chip lots in each factor sensitivity study. The sensitivity of the microINR® System to factors II, V, VII and X was estimated as 28%, 41%, 37% and 45%, respectively.
f) Analytical Specificity:
Endogenous and Exogenous Interferences:
Interference limits were established analyzing fresh venous whole blood, obtained from normal subjects and patients on vitamin K antagonist (VKA) therapy, spiked separately with the interferents.
The hematocrit range was evaluated for the microINR® System using blood samples from patients. Venous samples for INR determinations using the microINR® System, citrated plasma samples for the central laboratory INR (Instrumentation Laboratory ACL Elite PRO), and the measured venous whole blood hematocrit for each test subject were used in the analysis. Data analysis demonstrated that hematocrit range between 25 - 55% does not significantly affect test results.
g) Assay cut-off:
Not applicable.
9.2. Comparison Studies
a) Method comparison with Laboratory Reference device
Accuracy was evaluated by comparing the INR results of capillary samples measured on the microINR® System against the INR of venous plasma samples measured on Instrumentation Laboratory ACL TOP® 500 laboratory analyzer using HemosIL® RecombiPlasTin 2G recombinant human tissue thromboplastin reagent (reference device). Results of INR values measured on microINR® System fingerstick capillary whole blood samples were compared to the INR measured on ACL TOP® 500 with HemosIL® RecombiPlasTin 2G using venous plasma samples.
N: 260
Slope: 1.04
Intercept: 0.02
Pearson (r): 0.978
b) Matrix comparison
Not applicable, as the microINR® System is intended for use with capillary whole blood samples only.
9.3. Clinical Studies
a) Clinical Sensitivity: Not applicable
b) Clinical Specificity: Not applicable
c) Other clinical supportive data (when a) and b) are not applicable): Not applicable
9.4. Clinical cut-off
Not applicable.
9.5. Expected values/Reference range
A normal range study was conducted on 134 healthy subjects not on anticoagulation therapy across three sites. Capillary whole blood sample testing performed on the subjects not on vitamin K antagonist therapy demonstrated that 95% of the INR results ranged between 0.8-1.2.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Repeatability:
INR = 4.5: n test pairs=17*, SD=0.26, CV%=5.46
Device reproducibility data for high abnormal INR level plasma:
All Devices: N=90, Mean=3.45
Within-Run: SD=0.16, CV%=4.7
Between-Run: SD=0.04, CV%=1.0
Between-Day: SD=0.09, CV%=2.7
Between-Device: SD=0.00, CV%=0.0
Within-Device: SD=0.19, CV%=5.5
Device Reproducibility: SD=0.19, CV%=5.5
Reproducibility data for low abnormal INR level plasma:
All Devices: N=90, Mean=2.25
Within-Run: SD=0.11, CV%=4.9
Between-Run: SD=0.05, CV%=2.0
Between-Day: SD=0.00, CV%=0.0
Between-Device: SD=0.03, CV%=1.4
Within-Device: SD=0.12, CV%=5.3
Device Reproducibility: SD=0.12, CV%=5.5
Accuracy (Method comparison with Laboratory Reference device):
Pearson (r) = 0.978
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 864.7750 Prothrombin time test.
(a)
Identification. A prothrombin time test is a device used as a general screening procedure for the detection of possible clotting factor deficiencies in the extrinsic coagulation pathway, which involves the reaction between coagulation factors III and VII, and to monitor patients receiving coumarin therapy (the administration of one of the coumarin anticoagulants in the treatment of venous thrombosis or pulmonary embolism).(b)
Classification. Class II (performance standards).
0
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
January 25, 2019
iLine Microsystems S.L. Alberto Molinero Regulatory Affairs and Quality Manager Paseo Mikeletegi, 69 20009 Donostia, Guipúzcoa Spain
Re: K180780
Trade/Device Name: microINR System Regulation Number: 21 CFR 864.7750 Regulation Name: Prothrombin time test Regulatory Class: Class II Product Code: GJS. GGN Dated: March 22, 2018 Received: March 26, 2018
Dear Alberto Molinero:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal
1
statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801 and Part 809); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/CombinationProducts/GuidanceRegulatoryInformation/ucm597488.html; good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Leonthena R. Carrington -S
Lea Carrington Director Division of Immunology and Hematology Devices Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K180780
Device Name microINR System microINR Control Level A microINR Control Level B
Indications for Use (Describe)
microINR System:
The microlNR System (consisting of the microINR Chip) is intended for multiple-patient use by professional healthcare providers for the determination of International Normalized Ratio (INR) to monitor Oral Anticoagulation Therapy (OAT) warfarin. The microINR System uses fresh capillary whole blood. The microNR System is intended for in vitro diagnostic use at the point-of-care.
The microlNR System is intended for use in patients 18 years of age and older. Patients must be stabilized (≥ 6 weeks) on warfarin.
Caution: The microINR System is not intended for use in patients who are transitioning from heparin treatment to warfarin therapy. The microINR System is not intended to be used for screening purposes.
The microINR chips are only intended to be used with the microINR meter.
microINR Control Level A / microINR Control Level B:
The microlNR Control is intended for quality control performed on the microINR Meter when used with the disposable microINR Chips.
iLine Microsystems has available two microNR Control Levels (A and B) to perform quality control checks in the therapeutic range on the microINR System.
The microINR Control is intended for professional use only.
Type of Use (Select one or both, as applicable)
| ☑ Prescription Use (Part 21 CER 801 Subpart D) |
|---|
| ☐ Over-The-Counter Use (21 CER 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
Image /page/3/Picture/0 description: The image shows the logo for iLine microsystems. The logo is set against a blue background. The word "iLine" is in a stylized white font, with the "i" in lowercase and the rest of the word in uppercase. The registered trademark symbol is to the right of the word. Below "iLine" is the word "microsystems" in a smaller, white font.
510(k) Summary
This 510(k) summary is being submitted in accordance with the requirements of 21 CFR 807.92.
1. SUBMITTER INFORMATION
| Owner | iLine Microsystems, S.L. |
|---|---|
| Paseo Mikeletegi, 69 | |
| 20009 Donostia, Guipúzcoa | |
| Spain | |
| Contact | Alberto Molinero |
| amolinero@ilinemicrosystems.com | |
| Tel. +34 943 008 733 | |
| Fax: +34 943 008 737 | |
| Date Summary Prepared | January 18, 2019 |
2. DEVICE INFORMATION
| Proprietary Name | microINR® System
microINR® Control Level A
microINR® Control Level B |
|------------------|----------------------------------------------------------------------------|
| Common Name | Prothrombin time test |
| Panel | Hematology |
Regulatory Information:
| Classification | ||||
|---|---|---|---|---|
| Device | Regulation | |||
| Section | Device | |||
| Class | Product | |||
| Code | Test | |||
| microINR® System | 21 CFR 864.7750 | II | GJS | Prothrombin time test |
| microINR® Control Level A | 21 CFR 864.5425 | II | GGN | Plasma, coagulation |
| control | ||||
| microINR® Control Level B |
510k Premarket Notification
4
3. SUBSTANTIAL EQUIVALENCE INFORMATION:
| Element | Predicate Device |
|---|---|
| Predicate Device Name | CoaguChek® XS System |
| Common Name | Prothrombin time test |
| 510 (k) Number | K060978 |
| Manufacturer | Roche Diagnostics |
4. DEVICE DESCRIPTION:
The microINR® System is comprised of a portable measuring device (microINR® Meter) and test strips (microINR® Chips) in which the capillary blood sample flows through capillary action.
The microINR® Chip contains a reagent in dried form which consists of thromboplastin, and contains two symmetrical regions, the measuring channel and a control channel. The microINR® Meter measures International Normalized Ratio (INR) based on a Prothrombin Time (PT) assay carried out in the microINR® Chip based on microfluidic technology with machine vision detection.
The microINR® System has a multi-level On-board Quality Control. Multiple key functions and elements of the system are checked and if deviations are detected, error messages are displayed and test results are not reported.
In addition to the microINR® On-Board Controls, the microINR® Control has been developed as an optional liquid quality control solution. The microINR® Control must be used only by healthcare professionals in order to meet the regulatory compliance requirements applicable to the facility where they are to be used.
The microINR® Control contains lyophilized human citrated plasma from healthy donors (not heparinized plasma or plasma samples under oral anticoagulant therapy) modified by means of a dedicated process to simulate an abnormal coagulation sample and a calcium chloride solution. Before use, the lyophilized plasma must be reconstituted with the calcium chloride solution.
5
Image /page/5/Picture/0 description: The image is a logo for iLine microsystems. The logo is set against a blue background. The word "iLine" is written in white, with the "i" in lowercase and the "L" in uppercase. The word "microsystems" is written in a smaller font size below "iLine".
5. INDICATIONS FOR USE/INTENDED USE:
Intended Use of the microINR® System:
The microINR® System (consisting of the microINR® Meter and the microINR® Chip) is intended for multiple-patient use by professional healthcare providers for the determination of International Normalized Ratio (INR) to monitor Oral Anticoagulation Therapy (OAT) warfarin. The microINR® System uses fresh capillary whole blood. The microINR® System is intended for in vitro diagnostic use at the point-of-care.
The microINR® System is intended for use in patients 18 years of age and older. Patients must be stabilized (> 6 weeks) on warfarin.
Caution: The microINR® System is not intended for use in patients who are transitioning from heparin treatment to warfarin therapy. The microINR® System is not intended to be used for screening purposes.
The microINR® Chips are only intended to be used with the microINR® Meter.
Intended Use of the Optional Liquid Control:
The microINR® Control is intended for quality control performed on the microINR® Meter when used with the disposable microINR® Chips.
iLine Microsystems has available two microINR® Control Levels (A and B) to perform quality control checks in the therapeutic range on the microINR® System.
The microINR® Control is intended for professional use only.
6. SUMMARY COMPARISON OF TECHNOLOGICAL CHARACTERISTICS (PREDICATE):
The following table compares the microINR® System with its predicate device, CoaguChek® XS System (K060978).
6
Image /page/6/Picture/0 description: The image shows the logo for iLine microsystems. The logo is set against a blue background. The word "iLine" is written in white, with a small "R" in a circle next to it, indicating a registered trademark. Below "iLine", the word "microsystems" is written in a smaller font, also in white.
| Similarities | ||
|---|---|---|
| Item | microINR® System | CoaguChek® XS System (Predicate) |
| Intended Use/Indications for Use | The microINR® System (consisting of the microINR® Meter and the microINR® Chip) is intended for multiple-patient use by professional healthcare providers for the determination of International Normalized Ratio (INR) to monitor Oral Anticoagulation Therapy (OAT) warfarin. The microINR® System uses fresh capillary whole blood. The microINR® System is intended for in vitro diagnostic use at the point-of-care. The microINR® System is intended for use in patients 18 years of age and older. Patients must be stabilized (≥ 6 weeks) on warfarin. Caution: The microINR® System is not intended for use in patients who are transitioning from heparin treatment to warfarin therapy. The microINR® System is not intended to be used for screening purposes. The microINR® Chips are only intended to be used with the microINR® Meter. | The CoaguChek® XS system is intended for the use by professional healthcare providers for quantitative prothrombin time testing to monitor warfarin therapy, using fresh capillary or non-anticoagulated venous whole blood. |
| Similarities | ||
| Item | microINR® System | CoaguChek® XS System |
| (Predicate) | ||
| Sample type | Capillary whole blood. | Capillary or non- |
| anticoagulated venous whole | ||
| blood. | ||
| Test Strip Reagent | Human recombinant | |
| thromboplastin. | Same. | |
| Measuring Range | 0.8 – 6.0 INR. | 0.8 – 8.0 INR. |
| Hematocrit Range | Hematocrit ranges between | |
| 25-55% do not significantly | ||
| affect test results. | Same. | |
| Hemoglobin | No significant effect up to | |
| 1000 mg/dL. | Same. | |
| Calibration traceability | Each lot of test strips is | |
| calibrated to a reference lot | ||
| traceable to the WHO | ||
| International Reference | ||
| Preparation. | Same. | |
| Differences | ||
| Item | microINR® System | CoaguChek® XS System |
| (Predicate) | ||
| Operating | ||
| Principle/Technology | Microfluidic technology | |
| with machine vision | ||
| detection. | Electrochemical technology | |
| with amperometric (electric | ||
| current) detection of thrombin | ||
| activity | ||
| Test Strip Use Time | 6 hours. | 10 minutes.** |
| Test Strip Stability | 15 months. | 21 months. |
| Operating Temperature | 15 – 35°C (59 – 95°F). | 15 – 32°C (59 – 90°F).** |
| Minimum Sample Volume | A minimum of 3 µL. | A minimum of 8 µL.* |
| On-Board Quality Control | Multi-level on-board quality | |
| controls. | On-board fully integrated | |
| quality controls which use | ||
| electrochemical signals to | ||
| detect test strip integrity. | ||
| External Liquid Quality | ||
| Control | External optional liquid | |
| quality control: The | ||
| microINR® Control is | ||
| intended for quality control | ||
| performed on the | ||
| microINR® Meter when | ||
| used with the disposable | ||
| microINR® Chips. | ||
| iLine Microsystems has | ||
| available two microINR® | ||
| Control Levels (A and B) to | ||
| perform quality control | ||
| checks in the therapeutic | ||
| range on the microINR® | ||
| System. | ||
| The microINR® Control is | ||
| intended for professional | ||
| use only. | No external liquid quality | |
| control.** | ||
| Differences | ||
| Item | microINR® System | CoaguChek® XS System |
| (Predicate) | ||
| Memory Capacity | 199 (results with time and | |
| date.) | 300 test results with date and | |
| time. ** | ||
| Bilirubin | Bilirubin up to 40 mg/dL | |
| has no significant effect on | ||
| test results. | No significant effect up to 30 | |
| mg/dL. | ||
| Triglyceride | Lipemic samples containing | |
| up to 3270 mg/dL of | ||
| triglycerides have no | ||
| significant effect on test | ||
| results. | No significant effect up to 500 | |
| mg/dL. | ||
| Heparin | Use excluded in IFUs. | Unaffected by heparin |
| concentrations up to 0.8 U/mL. | ||
| Low Molecular Weight | ||
| Heparin | Use excluded in IFUs. | Insensitive to low molecular |
| weight heparins up to 2 IU | ||
| anti-factor Xa activity/mL. | ||
| Reference Range | INR: 0.8 to 1.2. | INR: 0.9 to 1.1. |
| Calibration | Automatic, encoded on | |
| disposable, no end user | ||
| input possible. | Lot specific code chip selected | |
| by end user. | ||
| Expiration date lock out | Automatic, encoded on | |
| disposable, no end user | ||
| input possible. | Lot specific code chip selected | |
| by end user. |
7
Image /page/7/Picture/0 description: The image features the logo for "iline microsystems." The logo is set against a blue background with rounded corners. The word "iline" is prominently displayed in white, with the "i" in lowercase and the rest of the letters in uppercase. A registered trademark symbol (®) is positioned to the upper right of "iline." Below "iline," the word "microsystems" is written in a smaller, sans-serif font, also in white.
8
Image /page/8/Picture/0 description: The image features the logo for iLine microsystems. The logo is set against a blue background with rounded corners. The word "iLine" is prominently displayed in white, with a registered trademark symbol to the right of the word. Below "iLine", the word "microsystems" is written in a smaller, sans-serif font, also in white.
9
Image /page/9/Picture/0 description: The image shows the logo for "iline microsystems". The logo is set against a blue background. The word "iline" is written in a bold, white sans-serif font, with a circled "R" trademark symbol in the upper right corner. Below "iline", the word "microsystems" is written in a smaller, lighter blue sans-serif font.
- CoaguChek® XS PT Test Instructions for Use (2017-09).
** CoaguChek® XS System User Manual (2016-08 USA).
10
Image /page/10/Picture/2 description: The image shows the logo for iLine microsystems. The logo is set against a blue background. The word "iLine" is written in a stylized font, with the "i" in lowercase and the rest of the word in uppercase. The word "microsystems" is written in a smaller font below "iLine."
7. STANDARD/GUIDANCE DOCUMENT REFERENCED:
CLSI EP05-A3 - Evaluation of Precision of Quantitative Measurement Procedures; Approved Guideline - Third Edition CLSI EP09-A3 - Measurement Procedure Comparison and Bias Estimation
Using Patient Samples; Approved Guideline - Third Edition
CLSI EP07-A2 - Interference Testing in Clinical Chemistry; Approved Guideline -Second Edition
CLSI EP25-A - Evaluation of Stability of In Vitro Diagnostic. Reagents; Approved Guideline - First Edition
CLSI EP28-A3c - Defining, Establishing, and Verifying, Reference Intervals in the Clinical Laboratory; Approved Guideline - Third Edition
CLSI H47-A2 - One-Stage Prothrombin Time (PT) Test and Activated Partial Thromboplastin Time (APTT) Test; Approved Guideline - Second Edition
CLSI H54-A - Procedures for Validation of INR and Local Calibration of PT/INR Systems: Approved Guideline - First Edition
8. TEST PRINCIPLE
The microINR® System is a handheld in vitro diagnostic medical device that uses microfluidic technology with machine vision detection to measure the prothrombin time from a fresh capillary (fingerstick) whole blood sample. The fresh capillary (fingerstick) whole blood sample is applied to the microINR® Chips (test strips) for testing. The microINR® Chip is inserted into the analyzer. Two microcapillary channels in the test strip are filled with the blood sample by capillary action. The microINR® Chip contains a preparation of human recombinant tissue factor, synthetic phospholipids and stabilizers. The microINR® Meter measures the International Normalized Ratio (INR) based on the Prothrombin Time (PT) assay carried out in the microINR® Chip and displays the International Normalized Ratio (INR) on the screen.
9. PERFORMANCE CHARACTERISTICS
The following internal performance data were provided in support of the substantial equivalence determination:
9.1. Analytical Performance
a) Precision/Repeatability:
Repeatability
The repeatability study was performed at three clinical sites, testing capillary samples from normal subjects and patients on warfarin therapy. Multiple Chip
11
Image /page/11/Picture/0 description: The image is a logo for "iLine microsystems". The logo is set against a blue background with rounded corners. The word "iLine" is written in a bold, sans-serif font, with the "i" in lowercase and the rest of the word in uppercase. A registered trademark symbol (®) is placed to the upper right of "iLine". Below "iLine", the word "microsystems" is written in a smaller, sans-serif font.
lots, Meters and Operators were included in the study. Two capillary samples (two fingersticks) were collected from each subject resulting into a total of 269 paired tests.
| Analysis per INR range | n test pairs | SD | CV% |
|---|---|---|---|
| INR |